LGALS3 and chronic kidney disease: In a press-release, the authors reported that 121 patients with chronic kidney disease were treated with a pharmacological Gal-3 inhibitor and significantly improved their glomerular filtration rate, uric acid, and blood urea nitrogen (BUN) levels, compared to placebo, between baseline and end of treatment.